Regeneron planning Phase II for REGN1979 in lymphoma following ASH readout

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) plans to start next year a "potentially registrational" Phase II trial of REGN1979 to treat relapsed or refractory follicular lymphoma after reporting an overall response rate (ORR) of 100% in a Phase I trial to treat relapsed or refractory B cell non-Hodgkin lymphoma (NHL). The Phase I data were presented at the American Society of Hematology (ASH) meeting in San Diego.

Among 10 evaluable patients with relapsed or refractory follicular lymphoma who received 5-40 mg doses of REGN1979, the ORR was 100%, including eight complete responses and two partial responses. The open-label, U.S. and German trial enrolled 68 patients to receive REGN1979 as monotherapy...